FM
fazen.markets
healthcare·esfritzh

Boston Scientific Prices $3B and €4.25B Notes for Penumbra Deal

12h ago|5 min readStandard
FM

Fazen Markets

Source: SEC EDGAR

Written by AI from a primary source ·

boston-scientificbsxsenior-notes-offeringpenumbra-acquisitionmedical-device-m-and-a

Key Takeaways

  • 1Boston Scientific has locked in roughly $7.5 billion of acquisition financing with a 101% redemption backstop that protects bondholders if the Penumbra deal collapses.

Partner

Trade the Markets Discussed in This Article

Regulated Broker Competitive Spreads

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Boston Scientific Corporation priced a dual-currency senior notes offering totaling $3.0 billion and €4.25 billion on November 19, 2026, the company announced, spanning ten tranches of USD and euro-denominated debt with coupons ranging from a floating rate to 5.875%. The Marlborough, Massachusetts-based medical device maker said proceeds will help fund the cash consideration for its acquisition of Penumbra, Inc., with both offerings expected to close December 1, 2026.

Context — Why Boston Scientific Is Raising $7.5 Billion Now

The offering arrives as Boston Scientific moves to finance a major acquisition. The company said it intends to use net proceeds from both offerings, together with short-term borrowings and cash on hand, to finance the cash consideration payable in connection with the Penumbra acquisition and to pay related fees and expenses.

What changed to trigger the raise now is the acquisition itself. The company framed the notes as acquisition financing, not general balance-sheet management, and attached a special mandatory redemption feature to every series — a structural signal that the deal timeline, not market conditions, is driving the issuance.

The report does not disclose the size of the Penumbra cash consideration, the acquisition price, or the expected closing date for the deal beyond the financing timeline. It also does not state Boston Scientific's existing use, cash balance, or credit ratings, so the incremental debt burden cannot be calculated from the report alone.

The macro backdrop for investment-grade issuance is visible in the coupons the company agreed to pay. The longest-dated euro tranche carries a 5.125% coupon due 2046, while the shortest fixed-rate USD tranche pays 5.375% due 2029 — a flat-to-inverted spread pattern that reflects where the curve sits rather than credit deterioration across maturities.

Each offering stands alone. The company said neither offering is conditioned upon the completion of the other, and neither is conditioned upon the Penumbra acquisition closing. That structure lets Boston Scientific price and settle both books independently while preserving a redemption escape hatch if the deal fails.

Data — The Numbers Behind the Ten-Tranche Raise

The USD offering totals $3.0 billion across four fixed-rate series: $1.0 billion of 5.375% senior notes due 2029, $750 million of 5.500% notes due 2031, $750 million of 5.750% notes due 2033, and $500 million of 5.875% notes due 2036.

The euro offering totals €4.25 billion across six series: €500 million of floating rate notes due 2028, €500 million of 3.875% notes due 2028, €750 million of 4.125% notes due 2030, €750 million of 4.500% notes due 2034, €1.0 billion of 4.750% notes due 2038, and €750 million of 5.125% notes due 2046.

TrancheSizeCouponMaturity
USD Notes$3.0B5.375%–5.875%2029–2036
Euro Notes€4.25BFloating–5.125%2028–2046

American Medical Systems Europe B.V., an indirect wholly owned finance subsidiary of Boston Scientific, is the issuer of the euro notes. Boston Scientific fully and unconditionally guarantees them.

The combined raise of roughly $7.5 billion at indicative exchange rates is split almost evenly between currencies, with the euro book slightly larger in notional terms. The longest USD maturity is 2036, while the euro curve extends a decade further to 2046 — giving the company a longer duration profile in euros than in dollars.

Analysis — What the Deal Structure Signals for Credit and Equity Desks

The special mandatory redemption at 101% of principal is the most consequential term. If the Penumbra acquisition does not close by the applicable special mandatory redemption end date, or if the issuer notifies the trustee that the company will not pursue completion, every series of USD and euro notes must be redeemed at 101% plus accrued interest. That caps downside for bondholders if the deal collapses.

Equity holders carry the deal risk that bondholders have hedged. BSX shareholders absorb the outcome if Penumbra does not close, while noteholders are protected by the redemption trigger. That asymmetry is standard in acquisition financing but worth marking when the deal is large enough to move the capital structure.

Sector exposure runs through medical technology peers and the broader investment-grade corporate market. A raise of this size competes for the same buyer base — insurers, pension funds, and IG credit funds — that absorbs other large healthcare and medtech issuance, though the report names no comparably sized peer deal.

The main limitation is what the report leaves out. No acquisition price, no pro forma use, no rating-agency actions, and no use-of-proceeds detail beyond the Penumbra cash consideration and general corporate purposes. Without those, the credit impact of adding roughly $7.5 billion of debt to the balance sheet cannot be sized from the report.

Positioning follows the structure. Bond desks are underwriting a deal with a 101% floor and an acquisition-linked redemption date, which narrows the spread they will accept. Equity desks hold the unhedged Penumbra closing risk, and the joint book-running managers — BofA Securities, Citigroup, and J.P. Morgan for the USD notes, and Barclays, Citigroup, and J.P. Morgan for the euro notes — are running two separate books.

Outlook — Catalysts and Levels to Watch

The first catalyst is the expected closing date. Both offerings are slated to settle December 1, 2026, subject to customary closing conditions. Any delay past that date would signal a problem with the financing rather than the acquisition.

The second is the Penumbra acquisition timeline itself. The special mandatory redemption end date is the hard deadline — if the deal does not close by then, the notes are called at 101%. The report does not disclose that date, so it is the single most important term still unknown to outside investors.

The third is the separate pricing of the two books. Because neither offering is conditioned on the other, one could close while the other is pulled, and the joint book-running manager lists differ between the USD and euro tranches.

On levels, the report names no secondary-market benchmarks, no spread guidance, and no reference yields. The only hard numbers are the coupons themselves: 5.375% to 5.875% in dollars and a floating rate to 5.125% in euros. Those coupons are the reference points to watch when the notes begin trading.

Frequently Asked Questions

What does Boston Scientific's notes offering mean for retail investors?

Retail investors generally cannot buy the notes directly, as they are sold through a prospectus to institutional buyers via the joint book-running managers. For shareholders, the relevant takeaway is that Boston Scientific is adding roughly $7.5 billion in debt to fund the Penumbra acquisition, while bondholders get a 101% redemption floor if the deal fails.

What happens if the Penumbra acquisition does not close?

Every series of USD and euro notes is subject to special mandatory redemption at 101% of aggregate principal, plus accrued and unpaid interest, if the acquisition is not completed by the applicable special mandatory redemption end date, or if the issuer tells the trustee it will not pursue the deal. The report does not disclose that end date.

Why did Boston Scientific price euro notes with longer maturities than the dollar notes?

The euro offering extends to 2046 while the longest USD tranche matures in 2036, and the euro book totals €4.25 billion versus $3.0 billion in dollars. The report does not explain the maturity choices, but the structure gives the company a longer duration profile in euros, with the euro notes guaranteed by Boston Scientific.

Bottom Line

Boston Scientific has locked in roughly $7.5 billion of acquisition financing with a 101% redemption backstop that protects bondholders if the Penumbra deal collapses.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.

PartnerPosition yourself for the macro moves discussed above

Start Trading
Share

Stay informed

Get market analysis delivered to your inbox.

Join 18,500+ investors

Sponsored

Ready to trade the markets?

Open a demo account in 30 seconds. No deposit required.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Related